Professional background

Shirley D'Sa, MD, FRCP, FRCPath, is a consultant haematologist and clinical lead for the UCLH Centre for Waldenström’s macroglobulinemia (WM) and Associated Disorders, and honorary associate professor at the UCL Cancer Institute. She is also haematological lead in the joint neurohaematology service at the National Hospital for Neurology, Queen Square, London.

Research interests

Dr D’Sa has a background in laboratory research into the recovery of immune function following allogeneic stem cell transplantation in myeloma patients.

  • UK Chief Investigator on a number of clinical trials in the field of Waldenström’s macroglobulinaemia and cold agglutinin disease including Phase I, II and II trials of novel therapies.
  • Co-investigator in the UCL/UCLH Biobank for Studying Health and Disease: biobanking samples from patients with Waldenström’s and IgM-related conditions
  • Co-investigator on NCI Genome-Wide Association Study (GWAS) of Lymphoid Malignancies and Related Disorders in collaboration with Dr Mary McMaster, Captain, US Public Health Service, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute
  • Chief Investigator and Data Custodian, Rory Morrison Registry: approved national clinical registry for Waldenström’s and Related Conditions which has >1100 patients’ data entered to date from 18 UK centres.

Dr D’Sa has worked with patients and colleagues to set up an not-for-profit organisation called WMUK (www.wmuk.org.uk), which seeks to bring health professionals and patients closer together to challenge the barriers faced by patients with Waldenström’s Macroglobulinaemia, and is an investigator on several clinical trials.

Publications

1999

  1. D'Sa S, Verfuerth S, Vyas P, et al. Early PCR-negativity after allogeneic BMT in adults with t(4;11) ALL in the absence of acute or chronic GVHD. Bone marrow transplantation 1999;23(7):695-6

2003

  1. D'Sa S, Peggs K, Pizzey A, et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. British journal of haematology 2003;123(2):309-22
  2. Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(4):257-65
  3. Peggs KS, Verfuerth S, D'Sa S, et al. Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation. British journal of haematology 2003;120(1):154-65

2004

  1. D'Sa S, Yong K, Kyriakou C, et al. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. British journal of haematology 2004;125(6):756-65

2005

  1. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. British journal of haematology 2005;130(3):363-72
  2. Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British journal of haematology 2005;129(6):763-70 d

2008

  1. Quinn JP, Mohamedbhai S, Chipperfield K, et al. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leukemia & lymphoma 2008;49(10):1995-8

2010

  1. Saifee TA, Elliott KJ, Rabin N, et al. Bortezomib-induced inflammatory neuropathy. Journal of the peripheral nervous system : JPNS 2010;15(4):366-8 doi: 10.1111/j.1529-8027.2010.00287.
  2. Sellar RS, Corbett EL, D'Sa S, et al. Treatment for lymph node tuberculosis. Bmj 2010;340:c63

2011

  1. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. British journal of haematology 2011;154(1):32-75

2012

  1. El-Sharkawi D, Basu S, Ocampo C, et al. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. Leukemia & lymphoma 2012;53(10):1949-52
  2. Morrow JM, D'Sa S, Page RA, et al. Rituximab responsive multiple radiculopathies and cranial nerve palsies in association with chronic lymphocytic leukaemia. Journal of neurology 2012;259(3):571-3
  3. Rabin N, Percy L, Khan I, et al. Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. British Journal of Haematology 2012;158(4):499-505

2013

  1. Groeneveldt L, Mein G, Garrod R, et al. A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. BMC cancer 2013;13:31
  2. Moore S, Atwal S, Sachchithanantham S, et al. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. European Journal of Haematology 2013;90(5):420-5

2014

  1. Pratt G, Bowcock S, Lai M, et al. United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. International journal of laboratory hematology 2013 doi: 10.1111/ijlh.12097
  2. Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D'Sa S. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol. 2014 Feb 15. doi: 10.1111/bjh.12760. [Epub ahead of print]
  3. Marzolini MA, Thomson KJ, Dorman J, D'Sa S.  BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience. Bone Marrow Transplant. 2014 Sep;49(9):1231-2
  4. Morgane Pihan, Michael Lunn, Shirley D'Sa, et al. Raised VEGF: USefulness in the diagnosis of POEMS syndrome. Journal of Neurology Neurosurgery & Psychiatry 09/2014; 85(10):e4-e4.

2015

  1. Jorge J Castillo, Shirley D'Sa, Michael P Lunn, et al. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. British Journal of Haematology 12/2015; DOI:10.1111/bjh.13883.
  2. Paul Maciocia, Mohsin Badat, Simon Cheesman, Shirley D'Sa, et al. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy. British Journal of Haematology. 12/2015; DOI: 10.1111/bjh.13867
  3. Aisling Carr, Zane Jaunmuktane, Sebastian Brandner, J Kothari, Julian Blake, Shirley D'Sa and Mike Lunn. The neuropathy spectrum of Waldenstroms macroglobulinaemia. Journal of Neurology Neurosurgery & Psychiatry 11/2015; 86(11):e4.60-e4.
  4. Aisling Carr, Shirley D'Sa,  A Arasaretnam, et al. PERIPHERAL NERVE BING-NEEL SYNDROME. Journal of Neurology Neurosurgery & Psychiatry 11/2015; 86(11):e4.59-e4.

2016

  1. Castillo JJ, D'Sa S, Lunn MP, et al. Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol 2016;172(5):709-15. doi: 10.1111/bjh.13883
  2. Maciocia P, Badat M, Cheesman S, et al. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy. Br J Haematol 2016;172(4):545-53
  3. Malhotra K, Butler JS, Yu HM, et al. Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing. BMC Cancer 2016;16:444
  4. Reyal Y, Popat R, Cheesman S, et al. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse. Br J Haematol 2016 doi: 10.1111/bjh.14086

2017

  1. Latifoltojar A, Hall-Craggs M, Rabin N, et al. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. Br J Haematol 2017;176(2):222-33
  2. Minnema MC, Kimby E, D'Sa S, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica 2017;102(1):43-51
  3. Maciocia N, Melville A, Cheesman S, et al. Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. Br J Haematol 2017;176(6):908-17
  4. Reyal Y, Popat R, Cheesman S, Rismani A, D'Sa S, Rabin N, Yong K. Real World Experience of Bortezomib Re-Treatment for Patients With Multiple Myeloma at First Relapse. Br J Haematol. 2017 May;177(3):495-497.
  5. Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Prevalence and Timing of TP53 Mutations in del(17p) Myeloma and Effect on Survival. Blood Cancer J. 2017 Sep 15;7(9):e610.
  6. D'Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations
  7. from the IWWM-8 consensus panel. Br J Haematol 2017;176(5):728-42.
  8. Pruppers MHJ, Merkies ISJ, Lunn MPT, Notermans NC; IMAGiNe Study Group.230th ENMC International Workshop:: Improving future assessment and research in IgM anti-MAG peripheral neuropathy: A consensus collaborative effort, Naarden, The Netherlands, 24-26 February 2017. Neuromuscul Disord. 2017 Nov;27(11):1065-1072.

2018

  1. Pihan M, Keddie S, D'Sa S, Church AJ, Yong KL, Reilly MM, Lunn MP. Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome. Neurol Neuroimmunol Neuroinflamm. 2018 Aug 15;5(5):e486.
  2. Fox TA, Lunn M, Wechalekar A, Bomanji J, Wan S, D'Sa S. [18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström's Macroglobulinemia. Haematologica. 2018 Jul;103(7)
  3. Keddie S, D'Sa S, Foldes D, Carr AS, Reilly MM, Lunn MPT. EMS neuropathy: optimising diagnosis and management. Pract Neurol. 2018 Aug;18(4):278-290.
  4. Vos JM, Notermans NC, D'Sa S, Lunn MP, van der Pol WL, Kraan W, Reilly MM, Chalker J, Gupta R, Kersten MJ, Pals ST, Minnema MC. High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):1007-1009.

2019

  1. Chen LY, Shah R, Cwynarski K, Lambert J, McNamara C, Mohamedbhai SG, Virchis A, Townsend W, D'Sa S, Ardeshna KM. Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab. Br J Haematol. 2019 Feb;184(3):462-465.
  2. Ziff OJ, Hoskote C, Keddie S, D'Sa S, Davangnanam I, Lunn MPT. Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. J Neurol. 2019 May;266(5):1067-1072. doi: 10.1007/s00415-019-09233-z. Epub 2019 Feb 12.
  3. Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Blood. 2019 Feb 28;133(9):893-901
  4. Keddie S, D'Sa S, Lunn MP. Advances in POEMS treatment and the need to define standardised outcome measures. Br J Haematol. 2019 Apr;185(2):386-388.
  5. Caimari F, Keddie S, Lunn MP, D'Sa S, Baldeweg SE. Prevalence and course of endocrinopathy in POEMS syndrome. J Clin Endocrinol Metab. 2019 Jun 1;104(6):2140-2146. 
  6. Tomkins O, Keddie S, Lunn MP, D'Sa S. High-dose therapy and autologous transplantation for POEMS Syndrome: effective, but how to optimise? Br J Haematol. 2019 Sep;186(6):e178-e181. doi: 10.1111/bjh.16057. Epub 2019 Jun 18.
  7. Keddie S, Fehmi J, Jaunmuktane Z, D'Sa S, Stevens JC, Lunn MP. Untangling a case of painful neuropathy.

Pract Neurol. 2019 Oct 4. pii: practneurol-2019-002370. doi: 10.1136/practneurol-2019-002370. [Epub ahead of print]

  1. Chavda SJ, Maciocia PM, Mesiri P, Counsell N, Kothari J, Bird A, Mariner C, Chew A, Clesham K, Moore S, Percy L, Rismani A, D'Sa S, Rabin N, Popat R, Yong K. A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1. Br J Haematol. 2019 Apr;185(2):350-353.
  2. Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Blood. 2019 Feb 28;133(9):893-901

2020

  1. Roger G Owen; Helen McCarthy; Simon Rule; Shirley D’Sa; Sheeba K Thomas; Olivier Tournilhac; Francesco Forconi; Marie José Kersten; Pier Luigi Zinzani; Sunil Iyengar; Jaimal Kothari; Monique C Minnema; Efstathios Kastritis; Thérèse Aurran-Schleinitz; Bruce D Cheson; Harriet Walter; Daniel Greenwald; Dih-Yih Chen; Melanie M Frigault; Ahmed Hamdy; Raquel Izumi; Priti Patel; Helen Wei; Sun Ku Lee; Diana Mittag;
  2. Richard R Furman. Acalabrutinib Monotherapy in Patients with Waldenström Macroglobulinemia. L Lancet Haematol. 2020 Feb;7(2):e112-e121. 
  3. Chen LY, Keddie S, Lunn MP, Bomsztyk J, Vitsaras E, Gupta R, D'Sa S. IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness. Br J Haematol. 2020 Feb;188(4):511-515.
  4. Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukas E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Froen HM, Hallstensen RF, Jaeger PH, Hjorth-Hansen H, Małecka A, Oksman MJ, Rolke J, Sekhar M, Sorbo JH, Tjonnfjord E, Tsykunova G, Tjønnfjord G. Cold Agglutinin Disease Revisited: A Multinational, Observational Study of 232 Patients. Blood. 2020 May 6:blood.2020005674. doi: 10.1182/blood.2020005674. Online ahead of print.
  5. Gelbenegger G, Schoergenhofer C, Derhaschnig U, Buchtele N, Sillaber C, Fillitz M, Schenk TM, D'Sa S, Cartwright R, Gilbert JC, Jilma B, Jaeger U. Inhibition of Complement C1s in Patients With Cold Agglutinin Disease: Lessons Learned From a Named Patient Program. Blood Adv. 2020 Mar 24;4(6):997-1005.
  6. Sayar Z, Weatherill A, Keddie S, Sive J, Lunn MP, Thomas M, D'Sa S. High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry. Blood Adv. 2020 May 26;4(10):2139-2142.
  7. Tomkins O, Berentsen S, Arulogun S, Sekhar M, D'Sa S. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol. 2020 Jul 11. doi: 10.1002/ajh.25932.
  8. Keddie S, Foldes D, Caimari F, Baldeweg SE, Bomsztyk J, Ziff OJ, Fehmi J, Cerner A, Jaunmuktane Z, Brandner S, Yong K, Manji H, Carr A, Rinaldi S, Reilly MM, D'Sa S, Lunn MP. Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study. Neurology. 2020 Jul 21;95(3):e268-e279. doi: 10.1212/WNL.0000000000009940. Epub 2020 Jun 30.
  9. Talaulikar D, Advani R, Branagan A, Buske C, Dimopoulos M, D'Sa S, et al. Consensus statement on the management of Waldenström Macroglobulinemia patients during the COVID-19 pandemic. Hemasphere. 2020 Jul 30;4(4):e433. doi: 10.1097/HS9.0000000000000433. eCollection 2020 Aug.
  10. Keddie S, Nagendran A, Cox T, Bomsztyk J, Jaunmuktane Z, Brandner S, Manji H, Rees JH, Ramsay AD, Rossor A, D'Sa S, Reilly MM, Carr AS, Lunn MP. Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. Muscle Nerve. 2020 Aug 12. doi: 10.1002/mus.27045. Online ahead of print.
  11. Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Talaulikar D, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E.
  12. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6.
  13. Marsh ES, Keddie S, Terris-Prestholt F, D'Sa S, Lunn MP. Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs. J Neurol Neurosurg Psychiatry. 2020 Oct 26:jnnp-2020-324012. doi: 10.1136/jnnp-2020-324012. Online ahead of print.
  14. Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844.
  15. Durot E, Kanagaratnam L, Zanwar S, Kastritis E, D'Sa S, Garcia-Sanz R, Tomowiak C, Hivert B, Toussaint E, Protin C, Abeykoon JP, Guerrero-Garcia T, Itchaki G, Vos JM, Michallet AS, Godet S, Dupuis J, Leprêtre S, Bomsztyk J, Morel P, Leblond V, Treon SP, Dimopoulos MA, Kapoor P, Delmer A, Castillo JJ. A prognostic index predicting survival in transformed Waldenström macroglobulinemia.Haematologica. 2020 Nov 12;Online ahead of print. doi: 10.3324/haematol.2020.262899.
  16. Alexander Röth, M.D.,1 Wilma Barcellini, M.D.,2 Shirley D’Sa, M.D.,3 Yoshitaka Miyakawa, M.D., Ph.D.,4 Catherine M. Broome, M.D.,5 Marc Michel, M.D.,6 David J. Kuter, M.D., D.Phil.,7 Bernd Jilma, M.D.,8 Tor Henrik Anderson Tvedt, M.D., Ph.D.,9 Joachim Fruebis, Ph.D.,10,a Xiaoyu Jiang, Ph.D.,11 Stella Lin, Ph.D.,11 Caroline Reuter, M.D., M.S.C.I.,11 Jaime Morales-Arias, M.D.,11,a William Hobbs, M.D., Ph.D.,11,a Sigbjørn Berentsen, M.D., Ph.D.12. Sutimlimab in Cold Agglutinin Disease. New England Journal of Medicine 2020 in press.